Results of first prospective trial using blood-based next-generation sequencing to identify candidates for treatment
Trial successfully identifies people with advanced non-small cell lung cancer for treatment with Alecensa
Trial successfully identifies people with advanced non-small cell lung cancer for treatment with Alecensa
Making high-value chemicals requires many years and large financial investment
X-Pulse offers capabilities previously available only on complex and expensive high-field NMR spectrometers
A pioneering commercialized fluorescence-based flow cytometry platform
Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer
The company launched the platform at the SynBioBeta 2019 conference in San Francisco
Women with a rare type of ovarian cancer could benefit from a drug that quadruples the likelihood of response compared with standard therapies
Rigaku is attending the 2019 Materials Science and Technology meeting to present it's latest X-ray analytical instrumentation
AMSBIO have introduced a new range of proprietary reagents designed for researchers investigating targeted cancer therapy.
Uniqsis offers an extensive range of individual flow chemistry modules that can be used on any flow chemistry system
The new CyFlow BrettCount test system is designed for fast and specific quantification of Brettanomyces bruxellensis in wine production
Cloud-based solution automates NGS data analysis for liquid biopsy and FFPE workflows
Delivers enhanced galactosylation for improved protein quality, and antibody binding and function
Flexible, modular system, designed for 21CFR Part 11 compliance
Innovation aims to improve productivity in the lab and enhance reliability and turnaround times in delivering results to patients
Approval puts company on track to offering a complete spectral flow cytometry solution to the Chinese market
The Thermo Scientific General Purpose Pro Centrifuge Series offers a powerful separation solution in an ergonomically enhanced design
Abbott's new technology is poised to be the first point-of-care blood test for assessing concussions, providing doctors results in 15 minutes